Skip to content
Pipeline

Therapeutic & Vaccine Candidates

Our green manufacturing platform enables rapid development of high-quality, novel biologics.  We’re advancing our pipeline of candidates to treat both human and animal diseases.

MFG Platform MFG
Human Health Programs
Hum Prgrms
Discovery
Disc
Pre-Clinical
Pre-Cl
Phase I
P I
Phase II
P II
FastPharming FastPharming FastPharming
Undisclosed Target 1
Oncology
Undisclosed Target 2
Oncology
Undisclosed Target 3
Oncology
ACE2-Fc
COVID-19
Animal Health Programs
Anml Prgrms
POC
POC
Pre-Clinical
P-C
Clinical Dev
CD
Product Registration
PR
FastPharming FastPharming FastPharming

Our focus in human health includes pulmonology, a field in which we’re developing a vaccine for COVID-19 disease as well as an anti-fibrotic therapeutic candidate, IBIO-100, for idiopathic pulmonary fibrosis, amongst other indications. Some studies1 have shown that a number of patients recovering from COVID-19 have severe pulmonary fibrosis sequelae. Another high unmet medical need disease area and a therapeutic focus for iBio is oncology. Our oncology pipeline is growing with three new programs entering the portfolio.

In the field of animal health, we’re developing a vaccine candidate, IBIO-400, for classical swine fever, a contagious, often fatal, disease affecting both feral and domesticated pigs. As a part of the program, we’ll seek USDA regulatory approvals, some of which will facilitate expansion into new market segments for our contract manufacturing services.

References

  1. Zou, H., Li, Sq. Pulmonary fibrosis in critically ill patients with novel coronavirus pneumonia during the convalescent stage and a proposal for early intervention. Acta Pharmacol Sin (2020). https://doi.org/10.1038/s41401-020-00566-4
Top